Jade Biosciences (NASDAQ:JBIO) Earns Buy Rating from HC Wainwright

Jade Biosciences (NASDAQ:JBIO)‘s stock had its “buy” rating reissued by stock analysts at HC Wainwright in a research note issued to investors on Thursday, MarketBeat Ratings reports. They currently have a $55.00 target price on the stock. HC Wainwright’s price target indicates a potential upside of 302.49% from the stock’s current price.

Several other research analysts have also commented on JBIO. Wedbush reissued an “outperform” rating and issued a $47.00 price objective on shares of Jade Biosciences in a research note on Thursday. BTIG Research raised their target price on shares of Jade Biosciences from $74.00 to $77.00 and gave the company a “buy” rating in a report on Monday, August 10th. UBS Group started coverage on shares of Jade Biosciences in a report on Monday, June 15th. They issued a “buy” rating and a $45.00 target price on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Jade Biosciences in a report on Friday, September 11th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and issued a $48.00 target price on shares of Jade Biosciences in a report on Tuesday, August 11th. Two equities research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Jade Biosciences has an average rating of “Moderate Buy” and an average price target of $51.75.

Jade Biosciences Price Performance

Shares of NASDAQ JBIO traded down $0.39 during midday trading on Thursday, hitting $13.67. The company’s stock had a trading volume of 84,929 shares, compared to its average volume of 746,557. The business’s fifty day simple moving average is $19.69 and its two-hundred day simple moving average is $19.74. Jade Biosciences has a 1 year low of $8.16 and a 1 year high of $28.00. The firm has a market capitalization of $869.09 million, a price-to-earnings ratio of -7.13 and a beta of 1.45.

Jade Biosciences (NASDAQ:JBIO) last posted its quarterly earnings data on Monday, August 10th. The company reported ($0.76) EPS for the quarter, missing the consensus estimate of ($0.66) by ($0.10). Analysts anticipate that Jade Biosciences will post -2.89 EPS for the current fiscal year.

Institutional Trading of Jade Biosciences

Several hedge funds have recently added to or reduced their stakes in the company. Janus Henderson Group PLC acquired a new stake in Jade Biosciences during the first quarter worth approximately $43,557,000. Baker BROS. Advisors LP acquired a new stake in Jade Biosciences during the fourth quarter worth approximately $25,323,000. Avidity Partners Management LP raised its holdings in Jade Biosciences by 24.3% during the fourth quarter. Avidity Partners Management LP now owns 1,400,708 shares of the company’s stock worth $21,613,000 after purchasing an additional 273,522 shares in the last quarter. Stempoint Capital LP acquired a new stake in Jade Biosciences during the first quarter worth approximately $2,164,000. Finally, Bank of New York Mellon Corp acquired a new stake in Jade Biosciences during the second quarter worth approximately $1,896,000.

Trending Headlines about Jade Biosciences

Here are the key news stories impacting Jade Biosciences this week:

• Positive Sentiment: HC Wainwright reaffirmed its “Buy” rating and set a $55 price target, implying substantial upside from the recent trading level. The bullish view provides analyst support for Jade’s pipeline and strategy. Benzinga report
• Positive Sentiment: JADE301 delivered favorable preclinical results in development for dermatomyositis. The half-life-extended anti-IFN-β antibody showed high-affinity and selective binding, greater functional potency than a dazukibart comparator in disease-relevant human cells, an approximately 25-day half-life in non-human primates, predictable muscle distribution, and good tolerability at evaluated subcutaneous doses. Jade Biosciences JADE301 preclinical data announcement
• Positive Sentiment: The company expects to begin a Phase 1 healthy-volunteer trial in the fourth quarter of 2026, with interim results anticipated in the second half of 2027. Advancing toward human testing is an important development milestone for JBIO. Jade Biosciences advances JADE301 toward Phase 1
• Neutral Sentiment: Jade’s presentations and conference call provided additional detail on JADE301’s profile and dermatomyositis opportunity, but the evidence remains preclinical and has not yet demonstrated safety or efficacy in humans. JADE301 program profile and preclinical data slideshow
• Negative Sentiment: Investors may be taking a cautious view because meaningful clinical readouts are not expected until 2027, while Jade remains an unprofitable biotechnology company. Its latest reported quarterly loss also exceeded analyst expectations, adding financial risk as development spending continues.

Jade Biosciences Company Profile

Jade Biosciences, Inc (NASDAQ: JBIO) is a clinical-stage biotechnology company focused on developing medicines for autoimmune and inflammatory diseases. The company uses antibody-based drug discovery and development approaches to pursue therapies intended to address significant unmet medical needs.

Jade Biosciences is advancing a pipeline of investigational programs and does not currently have commercially marketed products. Its work is centered on identifying and developing targeted therapies that may modulate biological pathways involved in autoimmune disease.

The company’s activities primarily consist of research, preclinical development and clinical evaluation of its drug candidates.